氨磺必利与奥氮平治疗女性精神分裂症的疗效及安全性被引量：2

下载PDF

导出

摘要目的:比较氨磺必利和奥氮平对女性精神分裂症患者的疗效与安全性。方法:将60例女性精神分裂症患者随机分组,治疗组30例选用氨磺必利进行治疗,对照组选用奥氮平治疗。观察12周,两组于治疗前及治疗后第2、4、8、12周末,评定阳性与阴性综合量表(PANSS)及治疗时出现的症状量表(TESS),评价临床疗效与不良反应。结果:两组治疗后2周的阳性与阴性综合量表(PANSS)评分减分率无显著差异(P>0.05)。经治疗后两组的血清泌乳素值均增加,两组比较无统计学差异(P>0.05),但治疗组出现月经改变的几率较对照组高(P<0.05);治疗组患者的体重升高发生率比对照组低(P<0.05)。结论:氨磺必利和奥氮平的疗效相当,氨磺必利引起月经改变现象较奥氮平多见,氨磺必利引起体重增加现象较奥氮平少见。

作者吴建凡吴新娇陈华云林文周春闽

机构地区福建福州神经精神病防治院

出处《北方药学》 2014年第6期22-23,共2页 Journal of North Pharmacy

关键词精神分裂症氨磺必利奥氮平

分类号 R749.3 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献2

1陈妍,陈美娟.氨磺必利在精神分裂症中的研究进展[J].神经疾病与精神卫生,2011,11(1):83-85. 被引量：70
2Ramaekers J G, Louwerens J W, Muntjewerff N D, et al. Psy-chomotor, cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic(haloperidol)antipsychotic[J]. Journal of clinical psy- chopharmacology, 1999,19( 3 ) : 209-221.

二级参考文献22

1Farde L, Wiesel FA, Halldin C, et al. Central D2 dopamine receptor occupancy in schizophrenic patients treated with anti psychotic drugs[J]. Arch Gen Psychiatry, 1988,45 (1) : 71 - 76.
2Kapur S,Zipursky R,Jones C,et al. Relationship between do pamine D2 occupancy, clinical response, and side effects: a double--blind PET study of first episode schizophrenia[J]. Am J Psychiatry,2000,157(4) :514-520.
3Sanofi--Aventis. Summary of product characteristics. Solian [J]. Available at: http://emc, medicines, org. uk/2008 (ac- cessed on 17 March 2009).
4Puech A,Fleurot O,Rein W. Amisulpride and atypical antip sychotic,in the treatment of acute episodes of schizophrenia: a dose--ranging study vs. haloperidol. The Amisulpride Study Group[J]. Acta Psychiatr Scand, 1998,98(1) :65-72.
5Stefan Leucht, Caroline Corves, Dieter Arbter. Second-- gener ation versus first--generation antipsychotic drugs for sehizo phrenia: a meta-analysis[J]. Lancet,2009,373:31-41.
6Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisul- pride. Amisulpride Study Group[J]. Am J Psychiatry, 1999, 156(4) :610-616.
7Deeks ED,Keating GM. Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression[J]. Drugs, 2008,68(8):1 115-1 137.
8Mortimer AM, Joyce E, Balasubramaniam K, et al. Treatment with amisulpride and olanzapine improve neuropsyehologicalfunction in schizophrenia[J]. Hum Psychopharmacol, 2007,22 (7) :445-454.
9Lecrubier Y, Boyer P, Turjanski S, et al. Amisulpride versus imipramine and placebo in dyslhymia and major depression. Amisulpride Study Group[J]. J Affect Disord, 1997,43(2): 95-103.
10Smeraldi E. Amisulpride versus fluoxetine in patients with dys- thymia or major depression in partial remission: a double blind,comparative study[J]. J Affect Disord, 1998,48(1): 47-56.